Fibroblast growth factor 21 plays a protective role in cardiovascular diseases by inducing autophagy.
- Author:
Ying-Kai LI
1
;
Song-Yuan HE
1
;
Cong WANG
1
;
Yu-Chen SHI
2
;
Jing-Hua LIU
3
Author Information
1. Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China.
2. Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China. shiyuchen0111@163.com.
3. Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China. liujinghua@vip.sina.com.
- Publication Type:Review
- MeSH:
Autophagy/physiology*;
Cardiovascular Diseases/metabolism*;
Fibroblast Growth Factors/metabolism*;
Humans;
Myocardial Reperfusion Injury/metabolism*
- From:
Acta Physiologica Sinica
2022;74(4):633-638
- CountryChina
- Language:Chinese
-
Abstract:
Fibroblast growth factor 21 (FGF21) is a growth factor with endocrine function in the fibroblast growth factor family. Previous reports have shown that FGF21 is involved in the regulation of energy metabolism and plays a protective role in cardiovascular diseases such as coronary heart disease, diabetes, non-alcoholic fatty liver disease and so on. Recent studies have found that FGF21 can induce autophagy in a variety of tissues and organs, and autophagy is involved in many pathological processes of cardiovascular diseases, including vascular calcification, atherosclerosis, and myocardial ischemia-reperfusion injury. Therefore, FGF21 may play a protective role in a variety of cardiovascular diseases by regulating autophagy. This article reviews the research progress on the protective role of FGF21 in cardiovascular diseases by inducing autophagy.
